MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.
+ 1 more risk
Medlab Clinical Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$8.00|
|52 Week High||AU$24.00|
|52 Week Low||AU$6.45|
|1 Month Change||-24.60%|
|3 Month Change||-33.67%|
|1 Year Change||-65.59%|
|3 Year Change||-85.59%|
|5 Year Change||-92.64%|
|Change since IPO||-73.33%|
Recent News & Updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For NowOct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?Oct 05
What We Learned About Medlab Clinical's (ASX:MDC) CEO PayFeb 21
Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three YearsDec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near FutureNov 22
|MDC||AU Biotechs||AU Market|
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -6.8% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -2.9% over the past year.
|MDC Average Weekly Movement||8.1%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||9.0%|
|10% most volatile stocks in AU Market||16.1%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MDC's weekly volatility (8%) has been stable over the past year.
About the Company
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Limited Fundamentals Summary
|MDC fundamental statistics|
Is MDC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDC income statement (TTM)|
|Cost of Revenue||AU$336.29k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.64|
|Net Profit Margin||-541.67%|
How did MDC perform over the long term?See historical performance and comparison